文献速递其他结缔组织病

特发性炎性肌病缺乏I、II、III型干扰素中和性自身抗体

Idiopathic inflammatory myopathies lack neutralising autoantibodies to type- I, II and III interferons.
PubMed 文献 · RMD Open · 2025-09-25

该研究在瑞典抗合成酶综合征(n=51)和皮肌炎(n=48)患者及献血者(n=100)的横断面观察队列中,采用平面和悬浮多重检测法筛查针对多种干扰素及其他细胞因子的自身抗体,并以1例自身免疫性多内分泌综合征1型(APS-1)患者作为生物学阳性对照。结果未在任何特发性炎性肌病患者亚组或献血者中检出抗I、II或III型干扰素自身抗体;除APS-1外,所有血浆样本均未显示对生理浓度IFN-α2的中和活性。结论认为该瑞典特发性炎性肌病队列中未检测到针对IFN-α的中和性自身抗体及其他类型干扰素的自身抗体。

要点

  • 在瑞典抗合成酶综合征和皮肌炎患者及献血者中未检出抗I、II或III型干扰素自身抗体。
  • 除APS-1阳性对照外,所有血浆样本均未中和生理浓度IFN-α2。
  • 该结果与其他I型干扰素过度活化的系统性自身免疫病(如系统性红斑狼疮)中存在的抗I型干扰素自身抗体形成对比。

核心结论

  • 在瑞典特发性炎性肌病队列中未检测到针对IFN-α的中和性自身抗体,也未检测到针对其他类型干扰素的自身抗体。
  • 这些发现与其他以I型干扰素过度活化为特征的系统性自身免疫病(如系统性红斑狼疮)中存在抗I型干扰素自身抗体的现象形成对比。

研究设计与样本

  • 横断面观察性队列研究,纳入瑞典抗合成酶综合征患者(n=51)和皮肌炎患者(n=48),并与来自一般人群的献血者(n=100)匹配。
  • 采用平面和悬浮多重检测法筛查针对多种干扰素及其他细胞因子的自身抗体。
  • 纳入1例已知携带中和I型干扰素自身抗体的自身免疫性多内分泌综合征1型(APS-1)患者作为参考生物学阳性。
  • 采用IFN-α/β应答细胞报告基因检测在体外测试自身抗体中和I型干扰素的功能能力。

主要发现

  • 初筛血浆样本显示特发性炎性肌病患者存在针对多种常见肌炎特异性及肌炎相关性抗原的自身抗体谱。
  • 筛查I、II或III型干扰素自身抗体时,未发现任何特发性炎性肌病患者亚组或一般人群献血者中存在抗干扰素自身抗体。
  • 除APS-1外,所有受检血浆样本均未显示对生理浓度IFN-α2的中和活性,进一步证实该队列完全缺乏针对IFN-α亚型的功能性自身抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether autoantibodies against interferons are present and play a role in disease modulation in idiopathic inflammatory myopathies (IIMs). METHODS: We screened for autoantibodies against a large number of interferons (IFNs) and other cytokines in a cross-sectional observational cohort of Swedish patients with anti-synthetase syndrome (n=51) and dermatomyositis (n=48), matched together with blood donors (n=100) from general population, using both planar and suspension-based multiplex assays. A single patient with autoimmune polyendocrine syndrome, type-1 (APS-1), known to harbour autoantibodies that neutralise type-I interferons, was included as a reference biological positive. The functional ability of autoantibodies to neutralise type-I interferons was tested in vitro, using an IFN-α/β responsive cell reporter assay. RESULT: The initial screening of plasma samples indicated a repertoire of autoantibodies in IIM patients against a number of common myositis-specific and myositis-associated antigens. On screening for autoantibodies against type-I, II or III interferons, we did not find any evidence of anti-IFN autoantibodies being present in any of the IIM patient subgroups or the blood donors from general population. Additionally, none of the tested plasma samples, except the APS-1, exhibited neutralisation of physiological concentration IFN-α2, further confirming a complete lack of functional autoantibodies against IFN-α subtypes in this cohort. CONCLUSIONS: We did not detect neutralising autoantibodies against IFN-α and autoantibodies against other types of IFNs in a Swedish cohort of IIM patients. These findings contrast with the presence of autoantibodies against type-I IFNs in other systemic autoimmune diseases, such as systemic lupus erythematosus, characterised by type-I IFN overactivation.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Behere A, Mildner H, Peralta Garcia I, et al. Idiopathic inflammatory myopathies lack neutralising autoantibodies to type- I, II and III interferons. RMD Open. 2025. PMID: 40998521. doi:10.1136/rmdopen-2025-005836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。